while i think an spa would have been preferable, even at the cost of some time, you seem to be convinced of this. but none of us really know how the FDA meeting went down, and more importantly we have no clue what discussions, if any, have taken place with potential suitors. so who's to say for sure what is better for the company. an SPA certainly derisks the program from a regulatory standpoint, but perhaps derisking the program clinically - and having that data before having to go to the markets to raise money or to a partner for money - is more important at this juncture? even in the long run, it is not totally clear to me what would maximize the present value of my shares a year from now - seling proellex for a higher premium because an SPA is in place, or having that share less diluted because the company was able to leverage data in 6 months before raising capital?
Market Data 
Markets 
AI
